Meeting abstract
https://doi.org/10.33004/reumatizam-supp-72-1-25
JAK inhibitori u bolesnika s visokim ka rdiovaskularnim rizikom – pro et contra
Mislav Radiž
*
* Corresponding author.
Full text: croatian pdf 653 Kb
page 35-35
downloads: 126
cite
APA 6th Edition
Radiž, M. (2025). JAK inhibitori u bolesnika s visokim ka rdiovaskularnim rizikom – pro et contra. Reumatizam, 72 (Supp 1), 35-35. https://doi.org/10.33004/reumatizam-supp-72-1-25
MLA 8th Edition
Radiž, Mislav. "JAK inhibitori u bolesnika s visokim ka rdiovaskularnim rizikom – pro et contra." Reumatizam, vol. 72, no. Supp 1, 2025, pp. 35-35. https://doi.org/10.33004/reumatizam-supp-72-1-25. Accessed 10 Jul. 2026.
Chicago 17th Edition
Radiž, Mislav. "JAK inhibitori u bolesnika s visokim ka rdiovaskularnim rizikom – pro et contra." Reumatizam 72, no. Supp 1 (2025): 35-35. https://doi.org/10.33004/reumatizam-supp-72-1-25
Harvard
Radiž, M. (2025). 'JAK inhibitori u bolesnika s visokim ka rdiovaskularnim rizikom – pro et contra', Reumatizam, 72(Supp 1), pp. 35-35. https://doi.org/10.33004/reumatizam-supp-72-1-25
Vancouver
Radiž M. JAK inhibitori u bolesnika s visokim ka rdiovaskularnim rizikom – pro et contra. Reumatizam [Internet]. 2025 [cited 2026 July 10];72(Supp 1):35-35. https://doi.org/10.33004/reumatizam-supp-72-1-25
IEEE
M. Radiž, "JAK inhibitori u bolesnika s visokim ka rdiovaskularnim rizikom – pro et contra", Reumatizam, vol.72, no. Supp 1, pp. 35-35, 2025. [Online]. https://doi.org/10.33004/reumatizam-supp-72-1-25
Abstract
Keywords
JAK inhibitori, veliki neželjeni kardiovaskularni događaji, arterijska hipertenzija, hiperlipidemija, pretilost, šećernu bolest
Hrčak ID:
339530
URI
https://hrcak.srce.hr/339530
Publication date:
5.11.2025.
Article data in other languages:
english
Visits: 415
*